ArticleScience advances2022
Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences.
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.Translational psychiatry · 2024Pooled it
- Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin.Molecular psychiatry · 2026Trial
- Threading the Needle: Practical Considerations for Merging Theory-Driven Computational Psychiatry With Data-Driven Analytics to Enhance Precision Health at Scale.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2026Review
- Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases.Schizophrenia bulletin · 2025Review
- Unveiling GABA and Serotonin Interactions During Neurodevelopment to Re-Open Adult Critical Periods for Neuropsychiatric Disorders.International journal of molecular sciences · 2025Review
- From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice.Pharmacology research & perspectives · 2025Review
- Benchmarking macaque brain gene expression for horizontal and vertical translation.Science advances · 2025Article
- Case Report: Intranasal esketamine combined with a form of generative artificial intelligence in the management of treatment-resistant depression.Frontiers in psychiatry · 2025Article
- Whole brain modelling for simulating pharmacological interventions on patients with disorders of consciousness.Communications biology · 2024Article
- Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Exploring Novel Antidepressants Targeting G Protein-Coupled Receptors and Key Membrane Receptors Based on Molecular Structures.Molecules (Basel, Switzerland) · 2024Review
- Deep CANALs: a deep learning approach to refining the canalization theory of psychopathology.Neuroscience of consciousness · 2024Article
- The unique neural signature of your trip: Functional connectome fingerprints of subjective psilocybin experience.Network neuroscience (Cambridge, Mass.) · 2024Article
- Representational maps in the brain: concepts, approaches, and applications.Frontiers in cellular neuroscience · 2024Review
- Patient-specific models link neurotransmitter receptor mechanisms with motor and visuospatial axes of Parkinson's disease.Nature communications · 2023Article
- Discovery andACS medicinal chemistry letters · 2023Article
- The default network dominates neural responses to evolving movie stories.Nature communications · 2023Article
- In vivo mapping of pharmacologically induced functional reorganization onto the human brain's neurotransmitter landscape.Science advances · 2023Article
- Dynamic regulation of the extracellular matrix in reward memory processes: a question of time.Frontiers in cellular neuroscience · 2023Review
- Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.Journal of psychopharmacology (Oxford, England) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Psychedelics probably alter states of consciousness by disrupting how the higher association cortex governs bottom-up sensory signals. Individual hallucinogenic drugs are usually studied in participants in controlled laboratory settings. Here, we have explored word usage in 6850 free-form testimonials about 27 drugs through the prism of 40 neurotransmitter receptor subtypes, which were then mapped to three-dimensional coordinates in the brain via their gene transcription levels from invasive tissue probes. Despite high interindividual variability, our pattern-learning approach delineated how drug-induced changes of conscious awareness are linked to cortex-wide anatomical distributions of receptor density proxies. Each discovered receptor-experience factor spanned between a higher-level association pole and a sensory input pole, which may relate to the previously reported collapse of hierarchical order among large-scale networks. Coanalyzing many psychoactive molecules and thousands of natural language descriptions of drug experiences, our analytical framework finds the underlying semantic structure and maps it directly to the brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.